Janice Holton

List of Publications by Year in Descending Order

306 papers	19,511 citations	75 h-index	131 g-index
324 ext. papers	22,307 ext. citations	7.6 avg, IF	6.25 L-index

#	Paper	IF	Citations
306	Prion-like synuclein pathology in the brain of infants with Krabbe disease.. *Brain*, **2022**,	11.2	2
305	Assembly of synuclein and neurodegeneration in the central nervous system of heterozygous M83 mice following the peripheral administration of synuclein seeds. *Acta Neuropathologica Communications*, **2021**, 9, 189	7.3	2
304	Reply to Qmpulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson disease: A [11C]-PHNO PET study.Q*Parkinsonism and Related Disorders*, **2021**, 93, 31-32	3.6	0
303	Identification of multiple system atrophy mimicking Parkinson disease or progressive supranuclear palsy. *Brain*, **2021**, 144, 1138-1151	11.2	7
302	Faster disease progression in Parkinson disease with type 2 diabetes is not associated with increased synuclein, tau, amyloid- or vascular pathology. *Neuropathology and Applied Neurobiology*, **2021**, 47, 1080-1091	5.2	2
301	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. *Movement Disorders*, **2021**, 36, 632-641	7	2
300	Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson disease dementia. *Neuropathology and Applied Neurobiology*, **2021**, 47, 143-156	5.2	8
299	Development of parkinsonism after long-standing cervical dystonia - A cohort. *Journal of the Neurological Sciences*, **2021**, 427, 117477	3.2	2
298	Neurodegenerative movement disorders: An epigenetics perspective and promise for the future. *Neuropathology and Applied Neurobiology*, **2021**, 47, 897-909	5.2	1
297	Association of clusterin with the BRI2-derived amyloid molecules ABri and ADan. *Neurobiology of Disease*, **2021**, 158, 105452	7.5	0
296	MOBP and HIP1 in multiple system atrophy: New synuclein partners in glial cytoplasmic inclusions implicated in the disease pathogenesis. *Neuropathology and Applied Neurobiology*, **2021**, 47, 640-652	5.2	4
295	Hippocampal synuclein pathology correlates with memory impairment in multiple system atrophy. *Brain*, **2020**, 143, 1798-1810	11.2	15
294	Epigenomics and transcriptomics analyses of multiple system atrophy brain tissue supports a role for inflammatory processes in disease pathogenesis. *Acta Neuropathologica Communications*, **2020**, 8, 71	7.3	2
293	Transcriptional profiling of multiple system atrophy cerebellar tissue highlights differences between the parkinsonian and cerebellar sub-types of the disease. *Acta Neuropathologica Communications*, **2020**, 8, 76	7.3	10
292	Neuropathological Findings in Ephedrone Encephalopathy. *Movement Disorders*, **2020**, 35, 1858-1863	7	3
291	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. *Acta Neuropathologica*, **2020**, 139, 717-734	14.3	8
290	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. *Acta Neuropathologica Communications*, **2020**, 8, 5	7.3	15

289	A novel frameshift deletion in autosomal recessive SBF1-related syndromic neuropathy with necklace fibres. *Journal of Neurology*, **2020**, 267, 2705-2712	5.5	0
288	Foix-Chavany-Marie syndrome due to type E TDP43 pathology. *Neuropathology and Applied Neurobiology*, **2020**, 46, 292-295	5.2	1
287	Corticospinal tract degeneration and temporal lobe atrophy in frontotemporal lobar degeneration TDP-43 type C pathology. *Neuropathology and Applied Neurobiology*, **2020**, 46, 296-299	5.2	3
286	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. *JAMA Neurology*, **2020**, 77, 377-387	17.2	44
285	Early presentation of urinary retention in multiple system atrophy: can the disease begin in the sacral spinal cord?. *Journal of Neurology*, **2020**, 267, 659-664	5.5	12
284	A case of TDP-43 type C pathology presenting as nonfluent variant primary progressive aphasia. *Neurocase*, **2020**, 26, 1-6	0.8	2
283	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. *Movement Disorders Clinical Practice*, **2020**, 7, 750-762	2.2	13
282	Signs of Chronic Hypoxia Suggest a Novel Pathophysiological Event in □ynucleinopathies. *Movement Disorders*, **2020**, 35, 2333-2338	7	5
281	A multimodal computational pipeline for 3D histology of the human brain. *Scientific Reports*, **2020**, 10, 13839	4.9	9
280	White matter DNA methylation profiling reveals deregulation of HIP1, LMAN2, MOBP, and other loci in multiple system atrophy. *Acta Neuropathologica*, **2020**, 139, 135-156	14.3	21
279	Expanding the molecular and phenotypic spectrum of truncating mutations. *Neurology: Genetics*, **2020**, 6, e381	3.8	9
278	Idiopathic inflammatory myopathy: Interrater variability in muscle biopsy reading. *Neurology*, **2019**, 93, e889-e894	6.5	10
277	Genetic and phenotypic characterisation of inherited myopathies in a tertiary neuromuscular centre. *Neuromuscular Disorders*, **2019**, 29, 747-757	2.9	4
276	Silver staining (Campbell-Switzer) of neuronal □ynuclein assemblies induced by multiple system atrophy and Parkinson□ disease brain extracts in transgenic mice. *Acta Neuropathologica Communications*, **2019**, 7, 148	7.3	19
275	A novel mutation in a family with diverse frontotemporal dementia spectrum disorders. *Journal of Physical Education and Sports Management*, **2019**, 5,	2.8	15
274	Neuropathological progression of clinical Parkinson disease subtypes. *Nature Reviews Neurology*, **2019**, 15, 361	15	3
273	Cerebral mitochondrial electron transport chain dysfunction in multiple system atrophy and Parkinson□ disease. *Scientific Reports*, **2019**, 9, 6559	4.9	24
272	Review: Clinical, neuropathological and genetic features of Lewy body dementias. *Neuropathology and Applied Neurobiology*, **2019**, 45, 635-654	5.2	17

271	Heritability and genetic variance of dementia with Lewy bodies. *Neurobiology of Disease*, **2019**, 127, 492-501	7.1	15
270	Exploring the putative role of kallikrein-6, calpain-1 and cathepsin-D in the proteolytic degradation of □synuclein in multiple system atrophy. *Neuropathology and Applied Neurobiology*, **2019**, 45, 347-360	5.2	10
269	LATE to the PART-y. *Brain*, **2019**, 142, e47	11.2	25
268	The genetic and clinico-pathological profile of early-onset progressive supranuclear palsy. *Movement Disorders*, **2019**, 34, 1307-1314	7	8
267	Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. *Brain*, **2019**, 142, 2813-2827	11.2	60
266	Lower nucleus accumbens □synuclein load and D3 receptor levels in Parkinson□ disease with impulsive compulsive behaviours. *Brain*, **2019**, 142, 3580-3591	11.2	6
265	Primum non nocere: a call for balance when reporting on CTE. *Lancet Neurology, The*, **2019**, 18, 231-233	24.1	34
264	Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing. *Acta Neuropathologica Communications*, **2019**, 7, 219	7.3	22
263	Luminescent conjugated oligothiophenes distinguish between □synuclein assemblies of Parkinson□ disease and multiple system atrophy. *Acta Neuropathologica Communications*, **2019**, 7, 193	7.3	19
262	Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 555-561	5.5	14
261	Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease. *JAMA Neurology*, **2019**, 76, 470-479	17.2	118
260	A comprehensive screening of copy number variability in dementia with Lewy bodies. *Neurobiology of Aging*, **2019**, 75, 223.e1-223.e10	5.6	10
259	Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features. *Neuropathology and Applied Neurobiology*, **2019**, 45, 495-512	5.2	24
258	Neuroaxonal Dystrophy/Neurodegeneration with Brain Iron Accumulation **2018**, 455-468		
257	Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers. *Brain*, **2018**, 141, 486-495	11.2	26
256	GYG1 causing progressive limb girdle myopathy with onset during teenage years (polyglucosan body myopathy 2). *Neuromuscular Disorders*, **2018**, 28, 346-349	2.9	5
255	Atypical periodic paralysis and myalgia: A novel phenotype. *Neurology*, **2018**, 90, e412-e418	6.5	27
254	Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype. *Annals of Neurology*, **2018**, 84, 485-496	9.4	28

253	The presubiculum is preserved from neurodegenerative changes in Alzheimer disease. *Acta Neuropathologica Communications*, **2018**, 6, 62	7.3	3
252	Pathological correlates of white matter hyperintensities in a case of progranulin mutation associated frontotemporal dementia. *Neurocase*, **2018**, 24, 166-174	0.8	24
251	Immunohistochemical and Molecular Investigations Show Alteration in the Inflammatory Profile of Multiple System Atrophy Brain. *Journal of Neuropathology and Experimental Neurology*, **2018**, 77, 598-607	3.1	12
250	Somatic copy number gains of synuclein (SNCA) in Parkinson disease and multiple system atrophy brains. *Brain*, **2018**, 141, 2419-2431	11.2	41
249	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. *Neurology*, **2018**, 90, 74-82	6.5	10
248	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. *Lancet Neurology, The*, **2018**, 17, 64-74	24.1	121
247	Development of phospho-specific Rab protein antibodies to monitor activity of the LRRK2 Parkinson disease kinase. *Biochemical Journal*, **2018**, 475, 1-22	3.8	79
246	Effect of Fluorinert on the Histological Properties of Formalin-Fixed Human Brain Tissue. *Journal of Neuropathology and Experimental Neurology*, **2018**, 77, 1085-1090	3.1	7
245	LRP10 in synucleinopathies. *Lancet Neurology, The*, **2018**, 17, 1033-1034	24.1	9
244	Reply to: Young- onset multiple system atrophy. *Movement Disorders*, **2018**, 33, 1975-1976	7	1
243	The aftermath of boxing revisited: identifying chronic traumatic encephalopathy pathology in the original Corsellis boxer series. *Acta Neuropathologica*, **2018**, 136, 973-974	14.3	19
242	Young-onset multiple system atrophy: Clinical and pathological features. *Movement Disorders*, **2018** , 33, 1099-1107	7	19
241	Disease-related patterns of in vivo pathology in Corticobasal syndrome. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 2413-2425	8.8	21
240	Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players. *Acta Neuropathologica*, **2017**, 133, 337-352	14.3	128
239	Clinicopathologic and molecular spectrum of -related mitochondrial disease. *Neurology: Genetics*, **2017**, 3, e149	3.8	14
238	LRRK2 levels and phosphorylation in Parkinson disease brain and cases with restricted Lewy bodies. *Movement Disorders*, **2017**, 32, 423-432	7	26
237	Calpainopathy with macrophage-rich, regional inflammatory infiltrates. *Neuromuscular Disorders*, **2017**, 27, 738-741	2.9	6
236	Biopsy pathology in a large cohort of juvenile dermatomyositis is heterogeneous and, for the most part, independent of autoantibody phenotype. *Canadian Journal of Neurological Sciences*, **2017**, 44, S6-S6	1	

235	Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. *Annals of Neurology*, **2017**, 81, 227-239	9.4	38
234	Homozygous mutation in causing distal vacuolar myopathy and motor neuropathy. *Neurology: Genetics*, **2017**, 3, e168	3.8	11
233	[P2241]: PATHOLOGICAL CORRELATES OF WHITE MATTER HYPERINTENSITIES ON CADAVERIC MRI IN PROGRANULIN-ASSOCIATED FRONTOTEMPORAL DEMENTIA **2017**, 13, P805-P805		
232	Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. *JAMA Neurology*, **2017**, 74, 970-976	17.2	94
231	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. *Neurobiology of Aging*, **2017**, 49, 214.e13-214.e15	5.6	10
230	Analysis of the prion protein gene in multiple system atrophy. *Neurobiology of Aging*, **2017**, 49, 216.e15-216.e18	5.6	4
229	Hypothalamic -synuclein and its relation to weight loss and autonomic symptoms in Parkinson's disease. *Movement Disorders*, **2017**, 32, 296-298	7	18
228	[P2158]: IS THE PRESUBICULUM PROTECTED FROM NEURODEGENERATIVE CHANGES? A PATHOLOGICAL AND BIOCHEMICAL INVESTIGATION **2017**, 13, P668-P668		
227	Antibody-Mediated Muscle Disease? **2017**, 203-206		
226	Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 633-41	5.5	8
225	MSA-C or SCA 17? A clinicopathological case update. *Movement Disorders*, **2016**, 31, 1582-1584	7	4
224	A genome-wide association study in multiple system atrophy. *Neurology*, **2016**, 87, 1591-1598	6.5	104
223	Targeting protein homeostasis in sporadic inclusion body myositis. *Science Translational Medicine*, **2016**, 8, 331ra41	17.5	69
222	Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. *Brain*, **2016**, 139, 3237-3252	11.2	80
221	Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series. *Lancet Neurology, The*, **2016**, 15, 1326-1335	24.1	109
220	Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis. *Arthritis and Rheumatology*, **2016**, 68, 2806-2816	9.5	67
219	DYT6 Dystonia: A Neuropathological Study. *Neurodegenerative Diseases*, **2016**, 16, 273-8	2.3	15
218	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. *American Journal of Human Genetics*, **2016**, 98, 500-513	11	225

217	Coenzyme Q10 Levels Are Decreased in the Cerebellum of Multiple-System Atrophy Patients. *PLoS ONE*, **2016**, 11, e0149557	3.7	30
216	A Clinical, Neuropathological and Genetic Study of Homozygous A467T POLG-Related Mitochondrial Disease. *PLoS ONE*, **2016**, 11, e0145500	3.7	33
215	Neuropathological criteria of anti-IgLON5-related tauopathy. *Acta Neuropathologica*, **2016**, 132, 531-43	14.3	107
214	Clinical features of the myasthenic syndrome arising from mutations in GMPPB. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 802-9	5.5	43
213	Tubular Aggregates and Cylindrical Spirals Have Distinct Immunohistochemical Signatures. *Journal of Neuropathology and Experimental Neurology*, **2016**, 75, 1171-1178	3.1	4
212	Cryptic Amyloidogenic Elements in the 3QUTRs of Neurofilament Genes Trigger Axonal Neuropathy. *American Journal of Human Genetics*, **2016**, 98, 597-614	11	37
211	CAV3 mutations causing exercise intolerance, myalgia and rhabdomyolysis: Expanding the phenotypic spectrum of caveolinopathies. *Neuromuscular Disorders*, **2016**, 26, 504-10	2.9	27
210	Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. *Neurobiology of Aging*, **2016**, 47, 218.e1-218.e9	5.6	29
209	Oculoleptomeningeal Amyloidosis associated with transthyretin Leu12Pro in an African patient. *Journal of Neurology*, **2015**, 262, 228-34	5.5	18
208	Zebra body myopathy is caused by a mutation in the skeletal muscle actin gene (ACTA1). *Neuromuscular Disorders*, **2015**, 25, 388-91	2.9	14
207	Histological evidence of chronic traumatic encephalopathy in a large series of neurodegenerative diseases. *Acta Neuropathologica*, **2015**, 130, 891-3	14.3	75
206	Neuropathology of Beta-propeller protein associated neurodegeneration (BPAN): a new tauopathy. *Acta Neuropathologica Communications*, **2015**, 3, 39	7.3	24
205	Deep brain stimulation of the subthalamic nucleus: histological verification and 9.4-T MRI correlation. *Acta Neurochirurgica*, **2015**, 157, 2143-7	3	10
204	A 30-unit hexanucleotide repeat expansion in C9orf72 induces pathological lesions with dipeptide-repeat proteins and RNA foci, but not TDP-43 inclusions and clinical disease. *Acta Neuropathologica*, **2015**, 130, 599-601	14.3	27
203	Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease. *Annals of the Rheumatic Diseases*, **2015**, 74, 204-10	2.4	39
202	Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. *Molecular Neurodegeneration*, **2015**, 10, 41	19	62
201	Rhabdomyolysis: a genetic perspective. *Orphanet Journal of Rare Diseases*, **2015**, 10, 51	4.2	73
200	Minimal change multiple system atrophy: an aggressive variant?. *Movement Disorders*, **2015**, 30, 960-7	7	30

199	The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis. *Neurobiology of Aging*, **2015**, 36, 1766.e1-1766.e3	5.6	13
198	Concomitant fragile X-associated tremor ataxia syndrome and Parkinson disease: a clinicopathological report of two cases. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 934-6	5.5	16
197	Analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism. *Neurobiology of Aging*, **2015**, 36, 1221.e1-6	5.6	32
196	C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. *Lancet Neurology, The*, **2015**, 14, 291-301	24.1	165
195	Multiple system atrophy is not caused by C9orf72 hexanucleotide repeat expansions. *Neurobiology of Aging*, **2015**, 36, 1223.e1-2	5.6	19
194	LETTER TO THE EDITOR Atypical Granulomatous Myositis and Pulmonary Sarcoidosis. *Open Rheumatology Journal*, **2015**, 9, 57-9	0.2	1
193	Neuropathological features of multiple system atrophy with cognitive impairment. *Movement Disorders*, **2014**, 29, 884-8	7	31
192	The novel Parkinson disease linked mutation G51D attenuates in vitro aggregation and membrane binding of -synuclein, and enhances its secretion and nuclear localization in cells. *Human Molecular Genetics*, **2014**, 23, 4491-509	5.6	153
191	Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. *Movement Disorders*, **2014**, 29, 857-67	7	148
190	Dysregulation of glucose metabolism is an early event in sporadic Parkinson disease. *Neurobiology of Aging*, **2014**, 35, 1111-5	5.6	129
189	Widespread RNA metabolism impairment in sporadic inclusion body myositis TDP43-proteinopathy. *Neurobiology of Aging*, **2014**, 35, 1491-8	5.6	25
188	Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant. *Neuropathology and Applied Neurobiology*, **2014**, 40, 149-63	5.2	58
187	From exercise intolerance to functional improvement: the second wind phenomenon in the identification of McArdle disease. *Arquivos De Neuro-Psiquiatria*, **2014**, 72, 538-41	1.6	14
186	Evaluating the relationship between amyloid- and -synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson disease. *Alzheimer's Research and Therapy*, **2014**, 6, 77	9	60
185	Inclusion body myositis: clinical review and current practice. *Clinical Practice (London, England)*, **2014**, 11, 623-637	3	
184	LRRK2 exonic variants and risk of multiple system atrophy. *Neurology*, **2014**, 83, 2256-61	6.5	34
183	A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. *BMJ Open*, **2014**, 4, e004552	3	63
182	A 29-year-old man with difficulty climbing the stairs. *Brain Pathology*, **2014**, 24, 549-50	6	

181	TDP-43 pathology is present in most post-encephalitic parkinsonism brains. *Neuropathology and Applied Neurobiology*, **2014**, 40, 654-7	5.2	8
180	Alpha-synuclein mRNA expression in oligodendrocytes in MSA. *Glia*, **2014**, 62, 964-70	9	121
179	Multiple system atrophy and repeat expansions in C9orf72. *JAMA Neurology*, **2014**, 71, 1190-1	17.2	5
178	Ongoing developments in sporadic inclusion body myositis. *Current Rheumatology Reports*, **2014**, 16, 477	4.9	13
177	Neuropathological features of genetically confirmed DYT1 dystonia: investigating disease-specific inclusions. *Acta Neuropathologica Communications*, **2014**, 2, 159	7.3	16
176	A 6.4 Mb duplication of the □synuclein locus causing frontotemporal dementia and Parkinsonism: phenotype-genotype correlations. *JAMA Neurology*, **2014**, 71, 1162-71	17.2	51
175	Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer. *Acta Neuropathologica Communications*, **2014**, 2, 24	7.3	16
174	The significance of □synuclein, amyloid-□and tau pathologies in Parkinson□s disease progression and related dementia. *Neurodegenerative Diseases*, **2014**, 13, 154-6	2.3	66
173	The novel MAPT mutation K298E: mechanisms of mutant tau toxicity, brain pathology and tau expression in induced fibroblast-derived neurons. *Acta Neuropathologica*, **2014**, 127, 283-95	14.3	27
172	MM2 subtype of sporadic Creutzfeldt-Jakob disease may underlie the clinical presentation of progressive supranuclear palsy. *Journal of Neurology*, **2013**, 260, 1031-6	5.5	17
171	Primary progressive aphasia with parkinsonism. *Movement Disorders*, **2013**, 28, 741-6	7	3
170	Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 1119-25	5.5	30
169	A novel prion disease associated with diarrhea and autonomic neuropathy. *New England Journal of Medicine*, **2013**, 369, 1904-14	59.2	93
168	Globular glial tauopathies (GGT): consensus recommendations. *Acta Neuropathologica*, **2013**, 126, 537-544	14.3	136
167	Neuropathological findings in benign tremulous parkinsonism. *Movement Disorders*, **2013**, 28, 145-52	7	56
166	The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. *Neurology*, **2013**, 80, 1856-61	6.5	114
165	TDP-43 pathology in a patient carrying G2019S LRRK2□mutation and a novel p.Q124E MAPT. *Neurobiology of Aging*, **2013**, 34, 2889.e5-9	5.6	33
164	Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias. *Neurobiology of Aging*, **2013**, 34, 1416-25	5.6	12

163	Strawberries on the brain--intracranial capillary hemangioma: two case reports and systematic literature review in children and adults. *World Neurosurgery*, **2013**, 80, 900.e13-21	2.1	17
162	Pantothenate kinase-associated neurodegeneration is not a synucleinopathy. *Neuropathology and Applied Neurobiology*, **2013**, 39, 121-31	5.2	35
161	Parkin disease: a clinicopathologic entity?. *JAMA Neurology*, **2013**, 70, 571-9	17.2	101
160	Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson disease and multiple system atrophy?. *Acta Neuropathologica*, **2013**, 125, 753-69	14.3	298
159	COX10 mutations resulting in complex multisystem mitochondrial disease that remains stable into adulthood. *JAMA Neurology*, **2013**, 70, 1556-61	17.2	24
158	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson disease. *Human Molecular Genetics*, **2013**, 22, 1039-49	5.6	96
157	Identification and quantification of oligodendrocyte precursor cells in multiple system atrophy, progressive supranuclear palsy and Parkinson disease. *Brain Pathology*, **2013**, 23, 263-73	6	52
156	Distal myopathy with cachexia: an unrecognised phenotype caused by dominantly-inherited mitochondrial polymerase mutations. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 107-10	5.5	14
155	Polymyositis, Dermatomyositis, and Inclusion Body Myositis **2013**, 298-312		3
154	Reply to letter: Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. *Movement Disorders*, **2013**, 28, 408	7	
153	Morphometric analyses of normal pediatric brachial biceps and quadriceps muscle tissue. *Histology and Histopathology*, **2013**, 28, 525-30	1.4	8
152	Authors response to scientific correspondence. *Neuropathology and Applied Neurobiology*, **2012**, 38, 381-381	5.2	
151	Review: genetics and neuropathology of primary pure dystonia. *Neuropathology and Applied Neurobiology*, **2012**, 38, 520-34	5.2	30
150	Difference in MSA phenotype distribution between populations: genetics or environment?. *Journal of Parkinsonʼs Disease*, **2012**, 2, 7-18	5.3	27
149	Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. *Neurobiology of Aging*, **2012**, 33, 814-23	5.6	151
148	Tau acts as an independent genetic risk factor in pathologically proven PD. *Neurobiology of Aging*, **2012**, 33, 838.e7-11	5.6	20
147	The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. *Neurobiology of Aging*, **2012**, 33, 2231.e7-2231.e14	5.6	57
146	High resolution MR anatomy of the subthalamic nucleus: imaging at 9.4 T with histological validation. *NeuroImage*, **2012**, 59, 2035-44	7.9	70

145	Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. *Movement Disorders*, **2012**, 27, 1754-62	7	126
144	Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. *Movement Disorders*, **2012**, 27, 1186-90	7	72
143	Diagnostic implications of histological analysis of neurosurgical aspirate in addition to routine resections. *Neuropathology*, **2012**, 32, 44-50	2	4
142	The neuropathology, pathophysiology and genetics of multiple system atrophy. *Neuropathology and Applied Neurobiology*, **2012**, 38, 4-24	5.2	179
141	096 Inclusion body myositis: a diagnostic challenge. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, e1.44-e1	5.5	
140	A case of necrotizing myopathy with proximal weakness and cardiomyopathy. *Neurology*, **2012**, 78, 1527-33	6.9	1
139	Genetic dysfunction of MT-ATP6 causes axonal Charcot-Marie-Tooth disease. *Neurology*, **2012**, 79, 1145-54	6.5	77
138	Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease. *Molecular Genetics and Metabolism*, **2011**, 103, 410-2	3.7	30
137	Mutational analysis of parkin and PINK1 in multiple system atrophy. *Neurobiology of Aging*, **2011**, 32, 548.e5-7	5.6	10
136	Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease. *Journal of Parkinson's Disease*, **2011**, 1, 277-86	5.3	74
135	LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study. *Neuropathology and Applied Neurobiology*, **2011**, 37, 777-90	5.2	37
134	TDP-43 pathology may occur in the BRI2 gene-related dementias. *Acta Neuropathologica*, **2011**, 121, 559-60	14.3	3
133	Neuropathology underlying clinical variability in patients with synucleinopathies. *Acta Neuropathologica*, **2011**, 122, 187-204	14.3	292
132	Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. *Acta Neuropathologica*, **2011**, 122, 415-28	14.3	60
131	Transportin1: a marker of FTLD-FUS. *Acta Neuropathologica*, **2011**, 122, 591-600	14.3	50
130	Targeting of the pedunculopontine nucleus by an MRI-guided approach: a cadaver study. *Journal of Neural Transmission*, **2011**, 118, 1487-95	4.3	26
129	Progressive parkinsonism, oculomotor abnormalities and autonomic dysfunction: clinicopathological case. *Movement Disorders*, **2011**, 26, 424-9	7	1
128	The effect of drug treatment on neurogenesis in Parkinson's disease. *Movement Disorders*, **2011**, 26, 45-50	7	29

127	Sodium and chloride channelopathies with myositis: coincidence or connection?. *Muscle and Nerve*, **2011**, 44, 283-8	3.4	4
126	Clinical and pathological heterogeneity in late-onset partial merosin deficiency. *Muscle and Nerve*, **2011**, 44, 590-3	3.4	17
125	Kearns-Sayre syndrome caused by defective R1/p53R2 assembly. *Journal of Medical Genetics*, **2011**, 48, 610-7	5.8	41
124	A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. *Brain*, **2011**, 134, 2548-64	11.2	65
123	Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. *Brain*, **2011**, 134, 2565-81	11.2	251
122	Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. *Brain*, **2011**, 134, 1493-1505	11.2	399
121	The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 1405-7	5.5	30
120	A two-stage meta-analysis identifies several new loci for Parkinson's disease. *PLoS Genetics*, **2011**, 7, e1002142	6	209
119	Does levodopa accelerate the pathologic process in Parkinson disease brain?. *Neurology*, **2011**, 77, 1420-6	6.5	45
118	A Huntington's disease phenocopy characterized by pallido-nigro-luysian degeneration with brain iron accumulation and p62-positive glial inclusions. *Neuropathology and Applied Neurobiology*, **2010**, 36, 551-7	5.2	11
117	Pupillary dysfunction in an atypical case of mitochondrial myopathy with tubular aggregates. *Journal of Neuro-Ophthalmology*, **2010**, 30, 153-6	2.6	1
116	PONM21 Electron microscopy does not add to the diagnostic accuracy of muscle biopsy for suspected mitochondrial disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, e65-e65	5.5	1
115	Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. *Brain*, **2010**, 133, 1755-62	11.2	280
114	POMD01 Blinded analysis of conventional MRI in a cohort of pathologically confirmed parkinsonian illnesses. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, e57-e57	5.5	1
113	Does corticobasal degeneration exist? A clinicopathological re-evaluation. *Brain*, **2010**, 133, 2045-57	11.2	302
112	Marked hemiatrophy in carriers of Duchenne muscular dystrophy. *Archives of Neurology*, **2010**, 67, 497-500		9
111	Cerebral amyloidosis: amyloid subunits, mutants and phenotypes. *Cellular and Molecular Life Sciences*, **2010**, 67, 581-600	10.3	43
110	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. *Acta Neuropathologica*, **2010**, 120, 33-41	14.3	198

109	Brain biopsy in dementia: clinical indications and diagnostic approach. *Acta Neuropathologica*, **2010**, 120, 327-41	14.3	49
108	Hyposmia in progressive supranuclear palsy. *Movement Disorders*, **2010**, 25, 570-7	7	38
107	Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. *Movement Disorders*, **2010**, 25, 638-42	7	30
106	PYROGLUTAMATE FORMATION AT THE N-TERMINI OF ABRI MOLECULES IN FAMILIAL BRITISH DEMENTIA IS NOT RESTRICTED TO THE CENTRAL NERVOUS SYSTEM **2010**, 61, S262-S269		1
105	Glucocerebrosidase mutations in clinical and pathologically proven Parkinson disease. *Brain*, **2009**, 132, 1783-94	11.2	488
104	A clinico-pathological study of subtypes in Parkinson disease. *Brain*, **2009**, 132, 2947-57	11.2	320
103	SNCA variants are associated with increased risk for multiple system atrophy. *Annals of Neurology*, **2009**, 65, 610-4	9.4	232
102	Can olfactory bulb biopsy be justified for the diagnosis of Parkinson disease? Comments on "olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders". *Acta Neuropathologica*, **2009**, 117, 213-4; author reply 217-8	14.3	19
101	Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. *Acta Neuropathologica*, **2009**, 118, 115-30	14.3	212
100	Regional differences in the severity of Lewy body pathology across the olfactory cortex. *Neuroscience Letters*, **2009**, 453, 77-80	3.3	96
99	Characterisation of a novel NR4A2 mutation in Parkinson disease brain. *Neuroscience Letters*, **2009** , 457, 75-9	3.3	31
98	Concomitant progressive supranuclear palsy and multiple system atrophy: more than a simple twist of fate?. *Neuroscience Letters*, **2009**, 467, 208-11	3.3	17
97	Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. *Journal of Neuropathology and Experimental Neurology*, **2009**, 68, 1073-83	3.1	132
96	Parkinson disease with Onuf nucleus involvement mimicking multiple system atrophy. *BMJ Case Reports*, **2009**, 2009,	0.9	2
95	Research in motion: the enigma of Parkinson disease pathology spread. *Nature Reviews Neuroscience*, **2008**, 9, 741-5	13.5	251
94	Lewy bodies in grafted neurons in subjects with Parkinson disease suggest host-to-graft disease propagation. *Nature Medicine*, **2008**, 14, 501-3	50.5	1293
93	Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. *Brain*, **2008**, 131, 1362-72	11.2	287
92	Expression of BRI2 mRNA and protein in normal human brain and familial British dementia: its relevance to the pathogenesis of disease. *Neuropathology and Applied Neurobiology*, **2008**, 34, 492-505	5.2	23

91	A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. *Brain*, **2008**, 131, 706-20	11.2	198
90	The use of nerve and muscle biopsy in the diagnosis of vasculitis: a 5 year retrospective study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2008**, 79, 1376-81	5.5	71
89	Parkinson's disease with Onuf's nucleus involvement mimicking multiple system atrophy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2008**, 79, 232-4	5.5	16
88	Neuropathology of primary adult-onset dystonia. *Neurology*, **2008**, 70, 695-9	6.5	38
87	Parietal lobe deficits in frontotemporal lobar degeneration caused by a mutation in the progranulin gene. *Archives of Neurology*, **2008**, 65, 506-13		48
86	Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. *Acta Neuropathologica*, **2008**, 115, 417-25	14.3	121
85	LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. *Acta Neuropathologica*, **2008**, 116, 639-46	14.3	38
84	Normal dopamine transporter single photon-emission CT scan in corticobasal degeneration. *Movement Disorders*, **2008**, 23, 2424-6	7	37
83	Quantification of normal range of inflammatory changes in morphologically normal pediatric muscle. *Muscle and Nerve*, **2008**, 37, 259-61	3.4	7
82	Preferential association of serum amyloid P component with fibrillar deposits in familial British and Danish dementias: similarities with Alzheimer's disease. *Journal of the Neurological Sciences*, **2007**, 257, 88-96	3.2	24
81	International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. *Arthritis and Rheumatism*, **2007**, 57, 1192-201		100
80	Conspicuous involvement of desmin tail mutations in diverse cardiac and skeletal myopathies. *Human Mutation*, **2007**, 28, 374-86	4.7	72
79	Shunt responsive progressive supranuclear palsy?. *Movement Disorders*, **2007**, 22, 902-3	7	15
78	The phenomenon of disproportionate antecollis in Parkinson's disease and multiple system atrophy. *Movement Disorders*, **2007**, 22, 2325-31	7	43
77	Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. *Movement Disorders*, **2007**, 22, 2235-41	7	188
76	Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. *Nature Genetics*, **2007**, 39, 1434-6	36.3	152
75	Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. *Brain*, **2007**, 130, 2123-8	11.2	145
74	Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1. *Human Molecular Genetics*, **2007**, 16, 2122-34	5.6	53

73	Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. *Brain*, **2007**, 130, 1566-76	11.2	289
72	NR4A2 genetic variation in sporadic Parkinson's disease: a genewide approach. *Movement Disorders*, **2006**, 21, 1960-3	7	14
71	UCHL-1 is not a Parkinson's disease susceptibility gene. *Annals of Neurology*, **2006**, 59, 627-33	9.4	107
70	PINK1 protein in normal human brain and Parkinson's disease. *Brain*, **2006**, 129, 1720-31	11.2	267
69	The alpha-synuclein gene in multiple system atrophy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2006**, 77, 464-7	5.5	38
68	Genetic alterations of the BRI2 gene: familial British and Danish dementias. *Brain Pathology*, **2006**, 16, 71-9	6	38
67	Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. *Journal of Neurochemistry*, **2006**, 98, 156-69	6	136
66	Autophagic vacuolar myopathy in twin girls. *Neuropathology and Applied Neurobiology*, **2006**, 32, 253-9	5.2	12
65	Molecular chaperons, amyloid and preamyloid lesions in the BRI2 gene-related dementias: a morphological study. *Neuropathology and Applied Neurobiology*, **2006**, 32, 492-504	5.2	24
64	An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. *Acta Neuropathologica*, **2006**, 111, 329-40	14.3	81
63	Sporadic and familial dementia with ubiquitin-positive tau-negative inclusions: clinical features of one histopathological abnormality underlying frontotemporal lobar degeneration. *Archives of Neurology*, **2005**, 62, 1097-101		25
62	Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. *Brain*, **2005**, 128, 2786-96	11.2	283
61	A common LRRK2 mutation in idiopathic Parkinson's disease. *Lancet, The*, **2005**, 365, 415-6	40	283
60	Knight's move thinking? Mild cognitive impairment in a chess player. *Neurocase*, **2005**, 11, 26-31	0.8	6
59	Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. *Brain*, **2005**, 128, 1247-58	11.2	583
58	Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. *Journal of the American College of Cardiology*, **2005**, 45, 922-30	15.1	125
57	Brain biopsy in dementia. *Brain*, **2005**, 128, 2016-25	11.2	105
56	Neuronal intranuclear inclusion disease: report on a case originally diagnosed as dopa-responsive dystonia with Lewy bodies. *Movement Disorders*, **2005**, 20, 1345-9	7	40

55	UCHL-1 gene in multiple system atrophy: a haplotype tagging approach. *Movement Disorders*, **2005**, 20, 1338-43	7	15
54	Gene expression in Huntington© disease skeletal muscle: a potential biomarker. *Human Molecular Genetics*, **2005**, 14, 1863-76	5.6	134
53	Familial Danish dementia: co-existence of Danish and Alzheimer amyloid subunits (ADan AND A{beta}) in the absence of compact plaques. *Journal of Biological Chemistry*, **2005**, 280, 36883-94	5.4	53
52	Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. *Archives of Neurology*, **2005**, 62, 1402-8		120
51	Unusual muscle disease in HIV infected patients. *Sexually Transmitted Infections*, **2004**, 80, 315-7	2.8	2
50	Pathological substrate for regional distribution of increased atrophy rates in progressive supranuclear palsy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2004**, 75, 1772-5	5.5	13
49	Frontotemporal lobar degeneration with ubiquitin-only-immunoreactive neuronal changes: broadening the clinical picture to include progressive supranuclear palsy. *Brain*, **2004**, 127, 2441-51	11.2	46
48	The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. *Brain*, **2004**, 127, 2657-71	11.2	359
47	Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. *Neuropathology and Applied Neurobiology*, **2004**, 30, 369-73	5.2	121
46	Is it really myositis? A consideration of the differential diagnosis. *Current Opinion in Rheumatology*, **2004**, 16, 684-91	5.3	33
45	Familial and sporadic cerebral amyloid angiopathies associated with dementia and the BRI dementias **2004**, 330-352		6
44	MHC Class I overexpression on muscles in early juvenile dermatomyositis. *Journal of Rheumatology*, **2004**, 31, 605-9	4.1	61
43	Polymyositis masquerading as mitochondrial toxicity. *Sexually Transmitted Infections*, **2003**, 79, 417-8	2.8	3
42	Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. *Journal of Neuropathology and Experimental Neurology*, **2003**, 62, 885-98	3.1	207
41	Neurofilament inclusion body disease: a new proteinopathy?. *Brain*, **2003**, 126, 2291-303	11.2	162
40	Anatamopathological spectrum of tauopathies. *Movement Disorders*, **2003**, 18 Suppl 6, S13-20	7	18
39	Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. *Neuropathology and Applied Neurobiology*, **2003**, 29, 288-302	5.2	167
38	Patients with a novel neurofilamentopathy: dementia with neurofilament inclusions. *Neuroscience Letters*, **2003**, 341, 177-80	3.3	76

37	Sporadic and familial cerebral amyloid angiopathies. *Brain Pathology*, **2002**, 12, 343-57	6	137
36	Evidence for pathological involvement of the spinal cord in motor neuron disease-inclusion dementia. *Acta Neuropathologica*, **2002**, 103, 221-7	14.3	24
35	Familial British dementia (FBD): a cerebral amyloidosis with systemic amyloid deposition. *Neuropathology and Applied Neurobiology*, **2002**, 28, 148-148	5.2	2
34	Human T cell leukaemia virus type I associated neuromuscular disease causing respiratory failure. *Journal of Neurology, Neurosurgery and Psychiatry*, **2002**, 72, 650-2	5.5	16
33	Complement activation in chromosome 13 dementias. Similarities with Alzheimer disease. *Journal of Biological Chemistry*, **2002**, 277, 49782-90	5.4	47
32	Distal myopathy with tubular aggregates: a new phenotype associated with multiple deletions in mitochondrial DNA?. *Journal of Neurology, Neurosurgery and Psychiatry*, **2002**, 73, 207-8	5.5	5
31	Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta. *Journal of Neuropathology and Experimental Neurology*, **2002**, 61, 254-67	3.1	102
30	A multidisciplinary team approach to skull base chondrosarcomas. *Journal of Neurosurgery*, **2001**, 95, 184-9	3.2	88
29	Systemic amyloid deposits in familial British dementia. *Journal of Biological Chemistry*, **2001**, 276, 43909-14	5.4	57
28	A pathogenic presenilin-1 deletion causes abberrant Abeta 42 production in the absence of congophilic amyloid plaques. *Journal of Biological Chemistry*, **2001**, 276, 7233-9	5.4	63
27	A multidisciplinary team approach to skull base chordomas. *Journal of Neurosurgery*, **2001**, 95, 175-83	3.2	131
26	Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia. *American Journal of Pathology*, **2001**, 158, 515-26	5.8	115
25	The dynamics of blood-brain barrier breakdown in an experimental model of glial cell degeneration. *Neuroscience*, **2001**, 103, 873-83	3.9	16
24	Chromosome 13 dementia syndromes as models of neurodegeneration. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2001**, 8, 277-84	2.7	26
23	Amyloidogenesis in familial British dementia is associated with a genetic defect on chromosome 13. *Annals of the New York Academy of Sciences*, **2000**, 920, 84-92	6.5	11
22	Gangliocytomas of the pituitary: a heterogeneous group of lesions with differing histogenesis. *American Journal of Surgical Pathology*, **2000**, 24, 607-13	6.7	70
21	Variant Alzheimer disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid- concentrations. *Annals of Neurology*, **2000**, 48, 806-808	9.4	113
20	Microdysgenesis with abnormal cortical myelinated fibres in temporal lobe epilepsy: a histopathological study with calbindin D-28-K immunohistochemistry. *Neuropathology and Applied Neurobiology*, **2000**, 26, 251-7	5.2	34

19	Skull base chordomas: correlation of tumour doubling time with age, mitosis and Ki67 proliferation index. *Neuropathology and Applied Neurobiology*, **2000**, 26, 497-503	5.2	49
18	A decamer duplication in the 3Q region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 4920-5	11.5	255
17	Variant Alzheimer disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid- concentrations **2000**, 48, 806		3
16	Variant Alzheimer disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations. *Annals of Neurology*, **2000**, 48, 806-8	9.4	37
15	Intracranial extracerebral follicular lymphoma mimicking a sphenoid wing meningioma. *Journal of Neurology, Neurosurgery and Psychiatry*, **1999**, 67, 251-2	5.5	12
14	Cytoskeletal pathology in familial cerebral amyloid angiopathy (British type) with non-neuritic amyloid plaque formation. *Acta Neuropathologica*, **1999**, 97, 170-6	14.3	52
13	Glutathione depletion increases brain susceptibility to m-dinitrobenzene neurotoxicity. *NeuroToxicology*, **1999**, 20, 83-90	4.4	10
12	Neuropathy target esterase: immunolocalization to neuronal cell bodies and axons. *Neuroscience*, **1998**, 83, 295-302	3.9	46
11	The effects of the tremorgenic mycotoxin penitrem A on the rat cerebellum. *Veterinary Pathology*, **1998**, 35, 53-63	2.8	59
10	Selective damage to the cerebellar vermis in chronic alcoholism: a contribution from neurotoxicology to an old problem of selective vulnerability. *Neuropathology and Applied Neurobiology*, **1997**, 23, 355-363	5.2	32
9	Increasing or decreasing nervous activity modulates the severity of the glio-vascular lesions of 1,3-dinitrobenzene in the rat: effects of the tremorgenic pyrethroid, Bifenthrin, and of anaesthesia. *Acta Neuropathologica*, **1997**, 93, 159-65	14.3	16
8	The glio-vascular toxicity of m-dinitrobenzene and related agents: modulation of toxicity by neuronal activation. *Archives of Toxicology Supplement*, **1996**, 18, 140-8		7
7	The bovine desmocollin family: a new gene and expression patterns reflecting epithelial cell proliferation and differentiation. *Journal of Cell Biology*, **1994**, 126, 507-18	7.3	66
6	Cloning and sequence analysis of desmosomal glycoproteins 2 and 3 (desmocollins): cadherin-like desmosomal adhesion molecules with heterogeneous cytoplasmic domains. *Journal of Cell Biology*, **1991**, 113, 381-91	7.3	171
5	Desmosomal glycoproteins 2 and 3 (desmocollins) show N-terminal similarity to calcium-dependent cell-cell adhesion molecules. *Journal of Cell Science*, **1990**, 97 (Pt 2), 239-46	5.3	17
4	Familial British and Danish Dementias515-526		2
3	Transcriptional profiling of Multiple System Atrophy cerebellar tissue highlights differences between the parkinsonian and cerebellar sub-types of the disease		1
2	Inherited Amyloidoses and Neurodegeneration: Familial British Dementia and Familial Danish Dementia439-445		